









Markets
/
Stocks
/
nasdaq-iobt
/

IO Biotech Inc

IOBT



View Detailed Chart

0.664USD

+0.042+6.83%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

46.31MMarket Cap

LossP/E TTM



IO Biotech Inc

0.664

+0.042+6.83%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+6.83%

5 Days

-17.72%

1 Month

-10.06%

6 Months

-48.88%

Year to Date

-27.77%

1 Year

-13.81%

View Detailed Chart

TradingKey Stock Score of IO Biotech Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IO Biotech Inc's Score

Industry at a Glance

Industry Ranking

226 / 501

Overall Ranking

400 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

2.463

Target Price

+227.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

IO Biotech Inc Highlights

StrengthsRisks

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.58, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 42.06M shares, decreasing 24.13% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 139.30K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 13.93.